Hikma Pharmaceuticals (HIK) Share Price, News & Analysis

Company Overview

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly. We are a trusted, reliable partner and dependable source of over 820+ (as of Feb 2026) high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe. We have 29 manufacturing facilities, 9 R&D centres and 9,500 employees worldwide.

Key Stats

• Today's Range: 1,451 to 1,480.36
• 50-Day Range: 1,236 to 1,495
• 52-Week Range: 1,187 to 2,146
• Volume: 419,157 shs
• Average Volume: 6.20 million shs
• Market Capitalization: £3.16 billion
• P/E Ratio: 8.13
• Dividend Yield: 4.34%
• Price Target: GBX 2,128
• Consensus Rating: Buy

Hikma Pharmaceuticals Stock Analysis - MarketRank™

Hikma Pharmaceuticals scored higher than 82% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.9 / 5
• Analyst Rating: Buy

Consensus Rating

Hikma Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on no strong buy ratings, 5 buy ratings, no hold ratings, and no sell ratings.

Upside Potential

Hikma Pharmaceuticals has a consensus price target of GBX 2,128, representing about 44.7% upside from its current price of GBX 1,471.

Amount of Analyst Coverage

Hikma Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Hikma Pharmaceuticals is 8.13, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.77.

Price to Earnings Ratio vs. Sector

The P/E ratio of Hikma Pharmaceuticals is 8.13, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 23.82.

Price to Earnings Growth Ratio

Hikma Pharmaceuticals has a PEG Ratio of 2.38. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Hikma Pharmaceuticals has a P/B Ratio of 1.43. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for HIK.

Dividend

• Score: 2.5 / 5
• Dividend Strength: Moderate

Dividend Leadership

Hikma Pharmaceuticals is a leading dividend payer. It pays a dividend yield of 4.34%, putting its dividend yield in the top 25% of dividend-paying stocks.

Dividend Growth

Hikma Pharmaceuticals does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Hikma Pharmaceuticals is 46.49%. This payout ratio is at a healthy, sustainable level, below 75%.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: 0.74

News Sentiment

Hikma Pharmaceuticals has a news sentiment score of 0.74. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.51 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for Hikma Pharmaceuticals this week, compared to 2 articles on an average week.

MarketBeat Follows

Only 1 people have added Hikma Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

Company Ownership

• Score: 1.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Hikma Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

17.28% of the stock of Hikma Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

63.62% of the stock of Hikma Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Drug Manufacturers - Specialty & Generic
• Sub-Industry: N/A
• Current Symbol: LON:HIK
• CIK: N/A
• Web: www.hikma.com
• Phone: +44-20-73992760
• Fax: N/A
• Employees: 9,100
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Hikma Pharmaceuticals: GBX 2,128
• High Price Target: GBX 2,400
• Low Price Target: GBX 1,800
• Potential Upside/Downside: +44.7%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): GBX 181
• Trailing P/E Ratio: 8.13
• Forward P/E Ratio: 9.64
• P/E Growth: 2.38
• Net Income: £353.21 million
• Net Margins: 12.00%
• Pretax Margin: N/A
• Return on Equity: 15.83%
• Return on Assets: 9.40%

Debt

• Debt-to-Equity Ratio: 63.59
• Current Ratio: 1.82
• Quick Ratio: 1.27

Sales & Book Value

• Annual Sales: £3.35 billion
• Price / Sales: 0.94
• Cash Flow: GBX 176.40 per share
• Price / Cash Flow: 8.34
• Book Value: GBX 1,027.88 per share
• Price / Book: 1.43

Miscellaneous

• Outstanding Shares: 214,854,000
• Free Float: N/A
• Market Cap: £3.16 billion
• Optionable: Not Optionable
• Beta: 0.64